Univariate survival analysis
| Median (months) | 12 months (%) | HR/95% CI | P value | |
| PFS | ||||
| CAIX/I* (low) | 4.2 | 22.2 | 1.8 (1.08 to 3.03) | 0.023 |
| CAIX/I (high) | 1.9 | 0 | Ref | |
| CD8† (low) | 1.9 | 5.6 | 0.79 (0.48 to 1.29) | 0.013 |
| CD8 (high) | 2.6 | 16.7 | Ref | |
| Low CAIX/I, low CD8 | 4.9 | 12.5 | Ref | 0.10 |
| Low CAIX/I, high CD8 | 3.6 | 30.0 | 0.82 (0.29 to 2.33) | |
| High CAIX/I, low CD8 | 1.4 | 0.0 | 2.64 (0.98 to 7.07) | |
| High CAIX/I, high CD8 | 2.6 | 0.0 | 1.64 (0.58 to 4.60) | |
| OS | ||||
| CAIX/I (low) | NR | 51.3 | 1.9 (1.02 to 3.49) | 0.036 |
| CAIX/I (high) | 8.1 | 14.1 | Ref | |
| CD8 (low) | 7.6 | 16.7 | 0.50 (0.26 to 0.94) | 0.006 |
| CD8 (high) | NR | 54.7 | Ref | |
| Programmed death-ligand 1 (PD-L1) (low) | 8.0 | 24.0 | Ref | 0.05 |
| Programmed death-ligand 1 (PD-L1) (high) | 8.0 | 42.0 | 0.63 (0.27 to 1.49) | |
| CD8/Treg (low) | 7 | 18.0 | Ref | 0.035 |
| CD8/Treg (high) | 9 | 50.0 | 0.53 (0.29 to 0.97) | |
| Low CAIX/I, low CD8 | 7.6 | 25.0 | Ref | 0.02 |
| Low CAIX/I, high CD8 | NR | 77.8 | 0.20 (0.04 to 1.02) | |
| High CAIX/I, low CD8 | 7.5 | 10.0 | 1.56 (0.56 to 4.29) | |
| High CAIX/I, high CD8 | 8.3 | 20.0 | 0.97 (0.30 to 3.20) |
The table shows variables that were found to be significant in univariate analysis. All variables were dichotomized (high vs low).
*CAIX/I=per cent area of CAIX/intensity of CAIX dichotomized.
†CD8=CD8 T cells normalized to tumor area.
OS, overall survival; PFS, progression free survival.